Sorry, your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Proof

PSMA+mCRPC ad campaign for Pluvicto. Image of a man standing in front of body parts with targeting rings

Targeted therapy goes nuclear

Combining state of the art PSMA testing with a targeted radioligand, AAA (Novartis) introduced LOCAMETZ and PLUVICTO for metastatic castration-resistant prostate cancer in 2022.

Pluvicto PSMA+mCRPC website displayed on a computer

Powered by Syneos Health

Part of Syneos Health Communications, GENICOS is a full-service, oncology-focused communications and advertising agency that specializes in transforming products into brands and patients into survivors. At GENICOS, cancer is more than a therapeutic category — it’s personal.

Locations

Columbus
500 Olde Worthington Road
Westerville, OH 43082
614.543.6011

New York
200 Vesey Street
New York, NY 10281
212.229.8400

Munich
Stefan George Ring 6
Munich, Germany 81929
+49 89 99 39 130